Defining long COVID using a population-based SARS-CoV-2 survey in California DOI Creative Commons
Jake M. Pry,

Kalyani McCullough,

Kristina Lai

и другие.

Vaccine, Год журнала: 2024, Номер 42(26), С. 126358 - 126358

Опубликована: Сен. 17, 2024

Язык: Английский

Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms: a systematic review of the literature DOI
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Raymart Macasaet

и другие.

Clinical Chemistry and Laboratory Medicine (CCLM), Год журнала: 2024, Номер 62(6), С. 1044 - 1052

Опубликована: Фев. 17, 2024

Viral persistence is one of the main hypotheses explaining presence post-COVID symptoms. This systematic review investigated SARS-CoV-2 RNA in plasma, stool, urine, and nasal/oral swab samples individuals with symptomatology.

Язык: Английский

Процитировано

15

COVID-19 therapeutics DOI
Daniele Focosi, Massimo Franchini, Fabrizio Maggi

и другие.

Clinical Microbiology Reviews, Год журнала: 2024, Номер 37(2)

Опубликована: Май 21, 2024

SUMMARYSince the emergence of COVID-19 in 2020, an unprecedented range therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy those often remains controversial or compromised by viral evolution. Uncertainties still persist regarding best therapies for high-risk patients, drug pipeline is suffering fatigue shortage funding. In this article, we review antiviral activity, mechanism action, pharmacokinetics, safety therapies. Additionally, summarize evidence from randomized controlled trials on various antivirals discuss unmet needs which should be addressed.

Язык: Английский

Процитировано

14

The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis DOI

Gangqiang Sun,

Ke Lin, Jingwen Ai

и другие.

Clinical Microbiology and Infection, Год журнала: 2024, Номер 30(12), С. 1505 - 1513

Опубликована: Июль 14, 2024

Язык: Английский

Процитировано

12

Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study DOI Creative Commons
Anna Camporesi, Rosa Morello,

Anna Rocca

и другие.

EClinicalMedicine, Год журнала: 2024, Номер 76, С. 102815 - 102815

Опубликована: Сен. 5, 2024

Язык: Английский

Процитировано

7

Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome DOI Creative Commons
Simon Haunhorst, Diana Dudziak, Carmen Scheibenbogen

и другие.

Infection, Год журнала: 2024, Номер unknown

Опубликована: Сен. 6, 2024

Язык: Английский

Процитировано

7

Prevalence and risk factors for long COVID in China: a systematic review and meta-analysis of observational studies DOI Creative Commons

Le-Yan Hu,

A. Cai,

Bo Li

и другие.

Journal of Infection and Public Health, Год журнала: 2025, Номер 18(3), С. 102652 - 102652

Опубликована: Янв. 5, 2025

With the outbreak of COVID-19 in China, a large number patients are at risk long COVID after recovery. The purpose our research is to systematically review existing clinical studies understand current prevalence and related factors China. protocol this systematic was registered on PROSPERO (CRD42024519375). We searched six electronic databases from 1st January 2020-1st March 2024. Literature screening, data extraction, bias assessment were independently carried out by two reviewers. Quality included evaluated AHRQ NOS. meta-analysis performed R software 4.2.3 derive factors. Overall, 50 with 65880 participants included. results showed that (with least one symptom) among approximately % (95 %Confidence Interval (CI) 42-58 %) Although we conducted meta-regression subgroup analysis, heterogeneity study high. But Omicron BA.2 variant had statistically significant effect (P = 0.0004). three most common symptoms fatigue (0.33, 95 %CI 0.28-0.39), cognitive decline (0.30, 0.14-0.46) shortness breath (0.29, 0.15-0.43). Patients severe acute phase (Odds Ratio (OR) 1.57, CI 1.39-1.77), combined 2 comorbidities (OR 1.80, 1.40-2.32), 3 2.13, 1.64-2.77), advanced age 1.02, 1.01-1.04), female 1.58, 1.44-1.73) for prevalence. Current found nearly half may suffering Establishing recovery-support platform regular follow-up would help long-term monitor manage patients, especially those high-risk population.

Язык: Английский

Процитировано

1

Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches DOI Creative Commons
Olga Adriana Căliman-Sturdza, Roxana Gheorghiţă, Andrei Lobiuc

и другие.

Life, Год журнала: 2025, Номер 15(3), С. 439 - 439

Опубликована: Март 11, 2025

The COVID-19 (C-19) pandemic has highlighted the significance of understanding long-term effects this disease on quality life those infected. Long (L-C19) presents as persistent symptoms that continue beyond main illness period, usually lasting weeks to years. One lesser-known but significant aspects L-C19 is its impact neuropsychiatric manifestations, which can have a profound effect an individual’s life. Research shows creates issues such mental fog, emotional problems, and brain symptoms, along with sleep changes, extreme fatigue, severe head pain, tremors seizures, pain in nerves. People cognitive problems plus fatigue mood disorders experience great difficulty handling everyday activities, personal hygiene, social interactions. Neuropsychiatric make people withdraw from activity hurt relationships, thus causing feelings loneliness. unpredictable state generates heavy psychological pressure through suffering, including depression anxiety. changes impairment, swings it hard for work or study effectively, decreases their output at school lowers job contentment. purpose narrative review summarize clinical data present literature regarding manifestations L-C19, identify current methods diagnosis treatment lead correct management condition, highlight these patients’

Язык: Английский

Процитировано

1

Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans DOI
Liang En Wee, Jue Tao Lim,

An Ting Tay

и другие.

Clinical Microbiology and Infection, Год журнала: 2024, Номер 31(1), С. 93 - 100

Опубликована: Авг. 28, 2024

Язык: Английский

Процитировано

4

Potential associations of selected polymorphic genetic variants with COVID-19 disease susceptibility and severity DOI Creative Commons
Orsolya Mózner, Edit Szabó, Anna Kulin

и другие.

PLoS ONE, Год журнала: 2025, Номер 20(1), С. e0316396 - e0316396

Опубликована: Янв. 3, 2025

In this study, we analyzed the potential associations of selected laboratory and anamnestic parameters, as well 12 genetic polymorphisms (SNPs), with clinical COVID-19 occurrence severity in 869 hospitalized patients. The SNPs by qPCR were based on population-wide (GWAS) data previously indicating association COVID-19, additional that have been shown to be important cellular processes also examined. We confirmed pre-existing diabetes found an unexpected between less severe disease loss smell taste. Regarding polymorphisms, a higher allele frequency LZTFL1 IFNAR2 minor variants significantly correlated greater susceptibility (hospitalization) severity, similar tendency was observed for RAVER1 MUC5B variants. Interestingly, ATP2B4 haplotype, protecting against malaria, increased susceptibility, while diabetic patients lower presence reduced-function ABCG2 transporter variant. Our current results, which should reinforced larger studies, indicate together may predictive value COVID-19.

Язык: Английский

Процитировано

0

A Machine-Learning Approach to Finding Gene Target Treatment Options for Long COVID DOI Creative Commons
Alejandro Lopez‐Rincon

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Фев. 13, 2025

Abstract Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), encompasses a range symptoms persisting for weeks or months after the acute phase COVID-19. These symptoms, affecting multiple organ systems, significantly impact quality life. This study employs machine-learning approach to identify gene targets treating COVID. Using datasets GSE275334, GSE270045, and GSE157103, Recursive Ensemble Feature Selection (REFS) was applied key genes associated with The highlights therapeutic potential targeting such PPP2CB, SOCS3, ARG1, IL6R, ECHS1. Clinical trials pharmacological interventions, including dual antiplatelet therapy anticoagulants, are explored their efficacy in managing COVID-19-related complications. findings suggest that machine learning can effectively biomarkers targets, offering promising avenue personalized treatment strategies COVID patients.

Язык: Английский

Процитировано

0